FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:410-414 January 27, 2005 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Klastersky, J. Related Article by Walsh, T. J. PubMed Citation

To the Editor: In the important study by Walsh et al. (Sept. 30 issue),¹ the most unexpected finding was the difference in response rates between the liposomal amphotericin B group and the caspofungin group among patients who had aspergillosis at baseline. The rate of response to liposomal amphotericin B (8.3 percent) is the lowest ever reported in the treatment of aspergillosis. This finding raises the question of whether there were imbalances between the treatment groups in terms of host factors (i.e., neutrophil recovery) or prior use of azole therapy, since sequential therapy with itraconazole and amphotericin B has been shown . . . [Full Text of this Article]

This article has been cited by other articles:

• Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 2.. Am J Health Syst Pharm 63: 1813-1820 [Abstract] [Full Text]